Baldness hair loss treatment covers a broad spectrum of options, from pharmacy products to prescription medicines and specialist procedures. Hair loss affects millions of people across the UK and can have a significant impact on confidence and wellbeing. Whether you are experiencing male- or female-pattern baldness, alopecia areata, or stress-related shedding, understanding the cause is the essential first step. This article outlines the most common causes of hair loss, what NHS and NICE guidance recommends, the treatments available, what to realistically expect, and how lifestyle choices can support your hair health.

Common Causes of Baldness and Hair Loss in the UK

Androgenetic alopecia is the most common cause of hair loss in the UK, affecting around 50% of men by age 50, driven by DHT-related follicle miniaturisation; other causes include alopecia areata, telogen effluvium, thyroid disorders, and iron deficiency anaemia.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss is a common concern affecting millions of people across the UK, with causes ranging from genetic predisposition to underlying medical conditions. Understanding the root cause is essential before considering any baldness hair loss treatment, as different conditions respond to different interventions.

Androgenetic alopecia (male- or female-pattern baldness) is the most prevalent form, affecting approximately 50% of men by the age of 50 and around 40% of women by the age of 70. It is driven by the hormone dihydrotestosterone (DHT), which causes progressive miniaturisation of hair follicles.

Other common causes include:

• Alopecia areata – an autoimmune condition causing patchy hair loss

• Telogen effluvium – diffuse shedding triggered by physical or emotional stress, illness, surgery, or nutritional deficiency

• Thyroid disorders – both hypothyroidism and hyperthyroidism can disrupt the hair growth cycle

• Iron deficiency anaemia – a particularly common cause in women of reproductive age

• Scalp conditions such as tinea capitis (scalp ringworm), which primarily affects children and requires systemic antifungal treatment and prompt referral; or seborrhoeic dermatitis, which may cause some temporary shedding but does not typically cause permanent hair loss

Certain medicines can also contribute to hair loss, including anticoagulants, chemotherapy agents, and some antidepressants. If hair loss begins shortly after starting a new medicine, it is worth discussing this with a GP or pharmacist.

A thorough clinical history and examination are the essential first steps. Blood tests should be guided by clinical findings and may include full blood count, ferritin, and thyroid function tests. Vitamin D or zinc levels should only be checked if there is a clinical indication or risk factors for deficiency — routine testing for these in hair loss is not standard practice. In women presenting with features of hyperandrogenism (such as hirsutism, menstrual irregularity, or signs of polycystic ovary syndrome), an androgen profile including total and free testosterone and sex hormone-binding globulin (SHBG) may also be appropriate.

Important red flags requiring urgent or expedited dermatology referral:

• Suspected scarring alopecia (indicated by scalp erythema, scaling, pain, pustules, or follicular loss) — early referral is essential to prevent permanent follicle destruction

• Tinea capitis in any patient — prompt treatment and specialist input are required

• Rapidly progressive or extensive hair loss

• Hair loss in children

For further information, the NHS hair loss page, NICE Clinical Knowledge Summary (CKS) on alopecia areata, and British Association of Dermatologists (BAD) patient information leaflets provide reliable, evidence-based guidance.

NHS and NICE Guidance on Hair Loss Treatments

Most hair loss treatments are not routinely commissioned on the NHS as they are considered cosmetic; NICE recommends watchful waiting for mild alopecia areata and has approved baricitinib for severe cases in adults meeting specific eligibility criteria.

The NHS acknowledges that hair loss can have a significant psychological impact, and GPs are encouraged to take patient concerns seriously. It is important to note, however, that many hair loss treatments are not routinely commissioned on the NHS, particularly when the condition is considered cosmetic rather than medically necessary. Local Integrated Care Board (ICB) policies vary, and patients should check what is available in their area.

NICE does not currently have a dedicated clinical guideline specifically for androgenetic alopecia, but it does provide guidance on related conditions. For alopecia areata, the NICE CKS recommends a watchful waiting approach in mild cases, as spontaneous regrowth occurs in many patients within 12 months. Topical or intralesional corticosteroids and referral to a dermatologist may be considered for more extensive or persistent cases.

For severe alopecia areata in adults, baricitinib (a JAK inhibitor) is now licensed in the UK and is the subject of a NICE Technology Appraisal. Where NICE criteria are met, it may be initiated by a specialist. Patients should be aware that this treatment requires specialist oversight, regular monitoring, and adherence to specific eligibility criteria.

For telogen effluvium, NICE-aligned practice focuses on identifying and correcting the underlying trigger — such as nutritional deficiencies or thyroid disease — rather than prescribing hair-specific treatments. The BAD also provides evidence-based patient information that GPs and dermatologists frequently reference.

When to seek medical advice:

• Sudden or rapid hair loss over a short period

• Hair loss accompanied by fatigue, weight changes, or skin changes

• Patchy or scarring hair loss (erythema, scaling, pain, or pustules on the scalp)

• Hair loss in children

• Any hair loss causing significant psychological distress

Patients are encouraged to visit their GP in the first instance, who can arrange appropriate investigations and, where necessary, refer to an NHS dermatologist. Suspected scarring alopecia or tinea capitis warrants urgent or expedited referral to prevent permanent hair loss. Private dermatology services are also widely available for those seeking faster access to specialist assessment.

Relevant guidance sources include the NICE CKS on alopecia areata, the NICE Technology Appraisal for baricitinib in severe alopecia areata, NHS hair loss pages, and BAD patient information.

Prescription and Over-the-Counter Treatment Options

Minoxidil is the main over-the-counter option for both sexes, while finasteride is a prescription-only medicine for men; baricitinib is licensed for severe alopecia areata and requires specialist oversight and monitoring.

Several evidence-based treatments are available for baldness and hair loss in the UK, ranging from pharmacy-purchased products to prescription medicines and procedural interventions.

Minoxidil is the most widely used treatment available without a prescription. It is available as a topical solution or foam in 2% and 5% concentrations and is licensed for both men and women. Its precise mechanism of action in hair growth is not fully understood, but it is thought to prolong the anagen (growth) phase of the hair cycle and increase follicle size. The legal category varies by product (some are Pharmacy-only medicines, others are General Sale List); patients should check the product label or ask a pharmacist. It must be applied consistently — typically once or twice daily — and results may take three to six months to become apparent.

Still have questions? Message our pharmacists for free →

Common adverse effects of minoxidil include local scalp irritation or contact dermatitis, and unwanted facial or body hair growth (hypertrichosis). Rare systemic effects such as hypotension or tachycardia have been reported. Minoxidil should not be used during pregnancy or breastfeeding; patients with cardiovascular conditions should seek medical advice before use. The Summary of Product Characteristics (SmPC) for the specific product, available via the Electronic Medicines Compendium (EMC), should be consulted for full prescribing information.

Finasteride (1 mg daily; available as a generic medicine) is a prescription-only medicine for men with androgenetic alopecia. It works by inhibiting the enzyme 5-alpha reductase, thereby reducing DHT levels and slowing follicle miniaturisation. It is not indicated for use in women and is contraindicated in pregnancy; women who are or may become pregnant should not handle crushed or broken tablets due to the risk of foetal harm.

Patients should be fully counselled on finasteride's safety profile before starting treatment. The MHRA issued a Drug Safety Update in 2024 highlighting the risks of depression, suicidal ideation, and persistent sexual dysfunction (including reduced libido, erectile dysfunction, and ejaculatory disorders) — effects that may continue after stopping the medicine. Patients experiencing mood changes or thoughts of self-harm should stop treatment and seek urgent medical advice. Breast changes (tenderness or enlargement) and potential effects on male fertility should also be discussed. Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Dutasteride is sometimes used off-label for androgenetic alopecia in men, but it is not licensed for this indication in the UK. It has a long half-life and a similar adverse effect profile to finasteride, including teratogenicity. It should only be considered under specialist supervision, with full counselling on risks.

For alopecia areata, treatments may include:

• Topical, intralesional, or systemic corticosteroids

• Topical immunotherapy (diphencyprone), administered in specialist centres

• Baricitinib — now licensed in the UK for severe alopecia areata in adults and subject to a NICE Technology Appraisal. It is initiated and monitored by a specialist. Key risks include serious infections, venous thromboembolism (VTE), and abnormalities in lipid and liver function tests, which require regular monitoring. Baricitinib must not be used during pregnancy; effective contraception is required during treatment and for a period after stopping. Patients should be counselled on these risks before starting.

In women with androgenetic alopecia and features of hyperandrogenism, anti-androgens such as spironolactone are sometimes used off-label under specialist supervision, with appropriate contraception and monitoring. Evidence for platelet-rich plasma (PRP) therapy and low-level laser therapy is currently limited and mixed; these are not routinely NHS-funded.

Hair transplant surgery (follicular unit transplantation or extraction) is a permanent procedural option available privately, but is not available on the NHS for cosmetic hair loss.

Key references: SmPCs for topical minoxidil products and finasteride 1 mg (EMC/medicines.org.uk); MHRA Drug Safety Update on finasteride (2024); NICE Technology Appraisal for baricitinib in severe alopecia areata; BAD guidance on androgenetic alopecia.

What to Expect from Hair Loss Treatment Over Time

Most hair loss treatments stabilise shedding or promote partial regrowth rather than full restoration, with results typically visible after three to six months; benefits are lost if treatment is stopped.

Setting realistic expectations is a crucial part of managing any baldness hair loss treatment plan. Most treatments slow the progression of hair loss or promote partial regrowth — they rarely restore a full head of hair to its original density, particularly in advanced cases.

With minoxidil, initial shedding in the first four to eight weeks is common and can be alarming, but this typically reflects the transition of resting hairs into the active growth phase. Visible improvement is generally seen after three to six months of consistent use. If treatment is stopped, any regrowth is usually lost within three to six months, as the underlying cause of hair loss remains unchanged.

Finasteride tends to stabilise hair loss within the first year, with modest regrowth possible in some men, particularly at the crown. Long-term studies suggest that continued use over five years or more is associated with better outcomes. As with minoxidil, discontinuation typically leads to resumption of hair loss progression.

For alopecia areata, the course is unpredictable. Mild cases often resolve spontaneously, while extensive or longstanding alopecia totalis (complete scalp hair loss) or universalis (total body hair loss) may be more resistant to treatment. Baricitinib, now licensed in the UK for severe alopecia areata in adults and subject to a NICE Technology Appraisal, has demonstrated meaningful regrowth in clinical trials. Its use requires specialist initiation, ongoing monitoring, and adherence to NICE eligibility criteria.

To support effective management, patients should be encouraged to:

• Maintain consistent treatment as directed by their clinician

• Document baseline appearance — photographs or validated scoring tools (such as the Severity of Alopecia Tool, SALT, for alopecia areata) can help assess response objectively

• Attend follow-up appointments — response should typically be reassessed at six to twelve months, with therapy adjusted if there is an inadequate response

• Seek psychological support if hair loss is significantly affecting mental wellbeing, as referral to counselling or support groups may be appropriate

• Plan for long-term adherence where treatments such as minoxidil or finasteride are effective, as discontinuation leads to loss of benefit

Further information is available from the NHS hair loss page and the NICE Technology Appraisal for baricitinib in severe alopecia areata.

Lifestyle Factors That May Affect Hair Loss and Regrowth

Iron, ferritin, zinc, and B vitamin deficiencies can worsen hair shedding, and crash dieting is a recognised trigger for telogen effluvium; lifestyle changes support medical treatment but are unlikely to reverse significant hair loss alone.

Whilst genetics and hormones play a dominant role in many forms of hair loss, lifestyle factors can meaningfully influence the health of the hair growth cycle and support the effectiveness of any baldness hair loss treatment.

Nutrition is particularly important. Deficiencies in iron, ferritin, zinc, and B vitamins have been associated with increased hair shedding. A balanced diet rich in lean proteins, leafy vegetables, nuts, seeds, and oily fish provides the micronutrients essential for healthy follicle function. Crash dieting or very low-calorie intake is a well-recognised trigger for telogen effluvium and should be avoided.

Supplements should only be taken if a deficiency has been confirmed by a clinician — evidence that routine supplementation with biotin, vitamin D, or zinc improves hair growth in people without a confirmed deficiency is limited. Patients taking high-dose biotin supplements should be aware that biotin can interfere with a range of laboratory tests, potentially causing misleading results. The MHRA has issued a Drug Safety Update on this issue; patients should inform their GP or any healthcare professional if they are taking biotin before having blood tests.

Stress management is equally relevant. Chronic psychological stress can disrupt the hair growth cycle and precipitate or worsen telogen effluvium. Techniques such as mindfulness, regular physical activity, and adequate sleep may help reduce stress-related hair shedding over time.

Hair care practices also warrant consideration:

• Avoid excessive heat styling, tight hairstyles (which can cause traction alopecia), and harsh chemical treatments

• Use gentle hair care products appropriate for your scalp type

• Avoid vigorous towel-drying, which can increase mechanical breakage

Smoking has been associated with accelerated androgenetic alopecia in some studies, likely due to its effects on microcirculation and oxidative stress. Whilst there is no specific NICE guidance linking smoking cessation to hair regrowth, quitting smoking offers broad health benefits and may be a worthwhile consideration.

Patients should be reassured that whilst lifestyle modifications alone are unlikely to reverse significant hair loss, they can support the effectiveness of medical treatments and contribute to overall scalp and follicle health.

Further information is available from the NHS hair loss page, the MHRA Drug Safety Update on biotin and laboratory test interference, and BAD patient information on telogen effluvium.

Frequently Asked Questions